Coding and billing — bill using the appropriate covered procedure code

Coverage for electrical stimulation services is tied to the specific procedure codes listed in the policy; bill using the most appropriate code(s) effective on the date of service (examples listed: CPT 97014, 97032; HCPCS G0283).

• Use CPT 97014, CPT 97032 or HCPCS G0283 when policy criteria are met
• Ensure codes are current as of the date of service; deleted or non‑effective codes may not be reimbursed

Prior authorization — no PA specified in these sections

This policy excerpt does not specify any routine prior authorization requirements for clinic‑based electrical stimulation services.

Prior authorization recommended for limited‑evidence modalities (H‑WAVE®, MENS, IFC)

For modalities with limited high‑quality evidence (for example H‑WAVE®, microcurrent/MENS, and IFC), prior authorization may be appropriate and should be supported by indication‑specific clinical rationale and documentation of prior conservative care.

• Provide indication‑specific rationale and prior conservative therapy records when requesting coverage for H‑WAVE®, MENS, or IFC
• Expect payer review of peer‑reviewed evidence due to limited/low‑quality data

PA may be required for modalities with insufficient evidence; NMES supported only in select adjunctive contexts

Some modalities with insufficient or mixed evidence (e.g., HVGS/HVPS, PENS/PNT) may prompt the payer to require prior authorization; NMES is supported in select populations but may require documentation showing adjunctive use and indication.

• For HVGS/HVPS and PENS/PNT, include peer‑reviewed evidence and rationale as part of PA requests
• When requesting NMES coverage, document that it is adjunctive to active exercise and that conservative care has failed as applicable

Prior authorization advisable when evidence is limited—esp. FES/NMES in neurologic rehab

Prior authorization is advisable when clinical evidence is limited or benefit is uncertain—particularly for FES/NMES used in neurologic rehabilitation where long‑term effectiveness is inconsistent; supply supporting trial data and rationale when requesting approval.

• Document short‑term functional gains and relevant trial evidence for FES/NMES in neurologic conditions
• Provide plan for reassessment and objective outcome measurement

Prior authorization — guidance not specified for clinic‑based electrical stimulation

The document sections provided do not state specific prior authorization requirements for clinic‑based electrical stimulation services or list operational PA code instructions.

Prior authorization guidance — no specific PA rules or billing codes stated

The policy excerpts do not list operational prior authorization instructions or specific billing codes tied to authorization decisions; clinical evidence summaries are presented without procedure‑level PA rules.

Prior authorization advised for neuromodulation and pelvic‑floor stimulation due to mixed evidence

Because neuromodulation and many pelvic‑floor stimulation modalities have mixed evidence and variable efficacy, prior authorization may be required to document indication, prior conservative care, and expected outcomes.

• Include prior conservative treatment (e.g., PFMT, bladder training) when requesting PA for neuromodulation or intravaginal stimulation
• Provide expected objectives and duration of therapy in the request

Prior authorization likely required for devices/modalities with insufficient peer‑reviewed evidence

Prior authorization is likely required for devices or modalities lacking peer‑reviewed evidence (examples named in the policy: Neufit Neubie, RST‑SANEXAS neoGEN® EcST, TEMPR/Scrambler/Calmare); requests risk denial without supporting published data.

• Supply peer‑reviewed published evidence when seeking coverage for these device‑specific or TEMPR modalities
• Absence of peer‑reviewed literature may result in denial

Prior authorization not present in this references segment

No prior authorization requirements are specified in the references section provided.

Prior authorization — not specified in reference entries

No prior authorization directives appear in the cited reference entries; the reference listings do not include PA instructions.

Prior authorization — none stated in this section

No prior authorization requirements are specified in this part of the document.

NMES for disuse atrophy — adjunct to active exercise; document indication and failed conservative care

NMES for disuse atrophy is considered medically necessary only when the nerve to the muscle is intact, it is used in conjunction with active exercise, and conservative/basic therapeutic exercises have failed (examples: major hip/knee surgery or prior immobilization).

• Document intact peripheral nerve supply to the target muscle
• Record failure to respond to basic therapeutic exercises or prior immobilization as the indication
• Confirm concurrent active exercise program in the medical record

Step therapy — none specified in these chunks

No step therapy algorithms or mandatory stepwise protocols are specified in the document excerpt.

Stepwise use — TENS generally adjunctive to exercise/multimodal therapy

Evidence supports exercise therapy and multimodal approaches; TENS is often used as an adjunct rather than first‑line monotherapy, suggesting stepwise use after or alongside standard conservative treatments.

• Prioritize exercise and multimodal rehabilitation; use TENS adjunctively to reduce pain or facilitate participation
• Document concurrent rehabilitation when using TENS

Step therapy — not explicitly stated

The policy excerpt does not define formal step therapy requirements.

FES/NMES as adjunct — conventional rehabilitation first, then consider ES adjunctively

Functional electrical stimulation (FES) and NMES should be considered adjuncts to standard rehabilitation; conventional rehabilitation is typically first‑line and FES/NMES is applied where trial data indicate benefit.

• Document that conventional rehab was attempted or is being provided alongside FES/NMES
• Provide objective baseline and follow‑up functional measures to demonstrate benefit

Step/sequence considerations — reassess and individualize FES vs AFO and training

Comparative evidence often contrasts FES with ankle‑foot orthoses (AFOs) and standard training; reassessment and individualized device selection over time are advised rather than assuming a fixed sequence.

• Reassess device effectiveness over time and document rationale for continued use
• Include comparative considerations (e.g., AFO vs FES) in treatment planning

Pelvic‑floor stimulation — no step therapy algorithm specified; compares to PFMT

No formal step therapy algorithms are specified for pelvic‑floor stimulation in these excerpts; evidence comparisons are presented versus pelvic floor muscle training and other active treatments.

Conservative‑first approach — PFMT/bladder training before adjunctive ES

Conservative interventions such as pelvic floor muscle training (PFMT) and bladder training are commonly first‑line for urinary incontinence; combination therapy (PFMT + ES or biofeedback) may be reasonable before progressing to less supported modalities.

• Document prior PFMT and bladder training before escalating to adjunctive electrical or neuromodulation therapies
• Include objective outcome measures (pad use, pad weight, leakage frequency) when escalating care

Stepwise use — established therapies before experimental modalities (e.g., TEMPR/Scrambler)

The policy advises considering conventional or guideline‑based therapies before approving experimental or poorly supported modalities (e.g., TEMPR/Scrambler), given the lack of high‑quality comparative trials.

• Require documentation of guideline‑based or conventional therapy attempts prior to trialing experimental modalities
• Supply trial‑level evidence if requesting coverage for TEMPR/Scrambler

Step therapy — none in references segment

No step therapy requirements are included in the references segment of the document.

Step therapy — none in cited reference section

No step therapy requirements are described in the referenced sections of the document.

Documentation — medical record must show response and stimulation parameters

When electrical stimulation is used, medical records must document the patient's response and the stimulation parameters specific to the modality (for example, low vs high frequency TENS, electrode placement), as policy requires documentation of response.

• Record modality, electrode placement, frequency/intensity, session duration, and observable clinical response
• Document baseline status and objective outcome measures to support ongoing necessity

Provider documentation — no additional visit/therapy documentation mandated in these chunks

No explicit provider documentation or visit/therapy documentation requirements are specified in some sections of the policy excerpt.

Required documentation elements — include indication, modality, parameters, and prior conservative care

Documentation should include the indication, modality used (e.g., TENS, MENS, H‑WAVE®), and dosing/parameters (intensity, frequency, session duration) where available, and prior conservative treatment to support the clinical rationale given variable evidence across modalities.

• Include prior conservative therapy and rationale for modality selection
• Record modality‑specific parameters: intensity, frequency, electrode size, session duration

NMES documentation guidance — document indication, concurrent rehab, parameters and frequency

When documenting NMES for orthopedic or disease‑related muscle weakness, include the indication, concurrent rehabilitation/exercise program, stimulation parameters, and treatment frequency to support its role as an adjunct to exercise.

• Document that NMES is used with an active exercise program and the rationale for adjunctive NMES
• Include stimulation parameters and planned dosing/schedule

Document NMES parameters and outcomes (post‑TKA guidance)

When NMES is used after total knee arthroplasty or knee surgery, document treatment parameters (for example frequency, intensity, electrode size), duration/dosing (sessions per day/weeks), and objective outcome measures of quadriceps strength and function.

• Record parameters cited in trials (e.g., intensity 100–120 mA; frequency 30–100 Hz; electrode size 100–200 cm2)
• Provide objective outcome measures such as quadriceps strength, TUG, 3‑minute walk, and WOMAC when available

Documentation — some sections do not specify requirements

No specific documentation requirements are provided in certain parts of the policy excerpt.

Documentation to support medical necessity — include validated outcome measures and objective assessments

To support medical necessity, include validated outcome measures and objective assessments where applicable (examples cited in dysphagia literature: FMA, ARAT, FOIS, PAS, SWAL‑QoL; use video‑fluoroscopic or endoscopic assessments when relevant).

• Include validated measures relevant to the indication (e.g., FMA for motor recovery, FOIS/PAS for dysphagia)
• Document objective testing (e.g., VFSS, FEES) when used to evaluate dysphagia outcomes

Supporting documentation required for intravaginal electrical stimulation — prior care, parameters, duration, and objective outcomes

When intravaginal electrical stimulation is considered, document prior conservative care, specific stimulation parameters, treatment duration, and objective outcome measures (pad use, pad weight, leakage frequency) because randomized trial evidence is variable and Often low quality.

• Show prior attempts at PFMT/bladder training and objective baseline urinary measures
• Record stimulation parameters and adherence to the intravaginal ES regimen

Documentation expectations for TEMPR/Scrambler — trial details, comparator, duration, and outcomes

When considering TEMPR/Scrambler therapy, documentation should include trial design details, comparator used, duration of follow‑up, prior conservative therapy, and objective outcome measures because available studies are small and heterogeneous.

• Provide details of prior conservative treatments attempted
• Include trial‑like documentation: session count/duration, comparators, and follow‑up outcome measures

Claims coding requirement — services without covered codes will be denied

Claims submitted for services not accompanied by covered code(s) under this policy will be denied as not covered; ensure the service is billed under a code listed as considered medically necessary when policy criteria are met.

• Verify that billed CPT/HCPCS codes match those listed (e.g., 97014, 97032, G0283) and that policy criteria are documented
• Claims without covered codes under this policy are subject to denial

Denial risks — none stated in this section

No additional denial risks are stated in this particular section of the document.

Denial risk for IFC — limited, heterogeneous evidence may trigger denial

Interferential current (IFC) studies are small, heterogeneous, and methodologically limited; lack of robust RCT data and inconsistent findings may be cited as reasons for denial when claims lack evidence of clinical benefit or appropriate indications.

• Be prepared to supply higher‑quality evidence and indication justification for IFC claims
• Methodologic limitations (small samples, heterogeneity) are common in IFC literature

HVGS evidence gap — insufficient outpatient evidence may lead to denial

There is insufficient evidence for safety and efficacy of high‑voltage galvanic/pulsed stimulation (HVGS/HVPS); this evidence gap may lead to non‑coverage or denial when billed as a distinct therapy without supporting human outpatient data.

• Document rationale and any relevant human outpatient data when requesting coverage for HVGS/HVPS
• Basic‑science parameters cited in literature may not be feasible in outpatient settings

PENS/PNT evidence gap — limited/low‑quality data may trigger denial

PENS/PNT evidence is limited, heterogeneous, and generally low quality for chronic pain; insufficient trial quality and inconsistent results may trigger coverage denial when claimed as proven therapies.

• Provide high‑quality RCT evidence and clear indication rationale if requesting coverage for PENS/PNT
• Expect scrutiny of trial quality and durability of effect

Denial risk — limited long‑term evidence for FES/NMES in neurologic conditions may lead to denial

Evidence gaps and lack of long‑term effectiveness data for FES/NMES in stroke and other neurologic conditions may trigger medical‑necessity denials when long‑term functional benefit is not demonstrated.

• Document short‑term functional gains and planned reassessment intervals when using FES/NMES in neurologic rehab
• Include objective measures showing activity or ADL improvement to justify continued coverage

No explicit authorization/denial triggers in these evidence summaries

No explicit authorization or billing denial triggers are stated in these evidence‑summary chunks; content focuses on study results and evidence quality rather than procedural denial rules.

No explicit authorization/denial triggers in these chunks

No explicit authorization or denial triggers are stated in the referenced chunks; the material emphasizes evidence summaries for indications rather than operational authorization rules.

Low‑quality evidence for CES may cause denial without stronger documentation

Cranial electrotherapy stimulation (CES) evidence quality is low and most trials show no benefit; poor‑quality evidence may prompt coverage denial or requests for stronger documentation.

• Include rigorous trial evidence if requesting CES coverage; absence of high‑quality positive trials risks denial
• Document prior conservative treatment and expected measurable outcomes

Denial risk for devices/therapies lacking peer‑reviewed evidence (Neubie, neoGEN®, TEMPR/Scrambler)

Requests for coverage of specific devices or therapies lacking peer‑reviewed published literature (for example Neufit Neubie, RST‑SANEXAS neoGEN® EcST, or TEMPR/Scrambler/Calmare) risk denial because safety and efficacy cannot be established from the available evidence.

• Absence of peer‑reviewed literature is cited as reason to treat these devices/therapies as unsupported
• Provide peer‑reviewed evidence to overcome default denial risk

No authorization/denial criteria in references‑only segment

No authorization or denial criteria are included in the references‑only segment of the document.

No authorization/denial instructions in reference entries

No authorization or denial instructions are present in the reference chunks cited; those chunks list citations only.